Elevated RBP4 levels were found to correlate with the fat percentage of the liver in many cohorts, confirming its importance as a biomarker for NAFLD screening in metabolic syndrome patients [28]. Here, RBP4 is linked to metabolic dysfunction-associated steatotic liver disease.